Venture
Odyssey Therapeutics, Inc.
Latest Form D 2025-12-04- CIK 1882782
- State MA
- Biotechnology
- 4 Form D offerings since 2021-10-14
- Total sold
- $591M
- across 4 offerings
- Rounds
- 4
- Form D offerings since 2021-10-14
- Latest round
- $214M
- 2025-12-04 · 021-565797
- Investors
- 55
- on the latest round
Connected
named in its Form D filingsOfferings · since 2021-10-144 Form D offeringsExemptions506(b)People · Item 3Gary D. Glick + 13 moreInvestors · dashboardInferred investors
Odyssey Therapeutics, Inc.CIK 1882782
Round timeline
amount sold · by first filed2025-12-04 · $214M
- 2021-10-14$91.6M021-417003
- 2022-10-27$168M021-462964
- 2023-12-15$117M021-499898
- 2025-12-04$214M021-565797
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($214M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-565797 | First filed2025-12-04 | Latest2025-12-04 | Sought$214M | Sold$214M | Investors55 | Exemptions506(b) |
| 021-499898 | First filed2023-12-15 | Latest2024-08-14 | Sought$121M | Sold$117M | Investors43 | Exemptions506(b) |
| 021-462964 | First filed2022-10-27 | Latest2022-10-27 | Sought$175M | Sold$168M | Investors34 | Exemptions506(b) |
| 021-417003 | First filed2021-10-14 | Latest2021-10-14 | SoughtIndefinite | Sold$91.6M | Investors63 | Exemptions506(b) |
Who backs Odyssey Therapeutics, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-12-04
| Name | Relationship | Clarification |
|---|---|---|
| Gary D. Glick | RelationshipExecutive Officer, Director | Clarification— |
| Carl Gordon | RelationshipDirector | Clarification— |
| Jill Carroll | RelationshipDirector | Clarification— |
| Valerie Odegard | RelationshipDirector | Clarification— |
| Nan Li | RelationshipDirector | Clarification— |
| Jeffrey Leiden | RelationshipDirector | Clarification— |
| Paulina Hill | RelationshipDirector | Clarification— |
| Timothy Walbert | RelationshipDirector | Clarification— |
| lan F. Smith | RelationshipDirector | Clarification— |
| Shelley Chu | RelationshipDirector | Clarification— |
| Ksenija Pavletic | RelationshipDirector | Clarification— |
| Carolyn Ng | RelationshipDirector | Clarification— |
| Nia Tatsis | RelationshipDirector | Clarification— |
| Jason Haas | RelationshipExecutive Officer | ClarificationCFO |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2021-10-14
- Latest filing
- 2025-12-04
Who backs Odyssey Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗